{
  "meta": {
    "timestamp": "2025-01-06T14:09:32.174279",
    "version": "1.0",
    "type": "search_analysis"
  },
  "companies": [
    {
      "company_name": "Tourmaline Bio Inc.",
      "symbol": "TRML",
      "analysis": {
        "historical": {
          "risk_score": 65,
          "key_risks": [
            "Regulatory Risks: Dependence on FDA and EMA approvals for clinical trials and drug approvals.",
            "Funding Challenges: Reliance on external funding, including venture capital and public markets.",
            "Clinical Trial Setbacks: Risks related to adverse events or failure to meet primary endpoints.",
            "Competitive Landscape: Intense competition in oncology and autoimmune diseases.",
            "Intellectual Property Disputes: Potential legal challenges over patents or proprietary technologies."
          ],
          "controversies": [
            "Potential disputes arising from the licensing agreement with Pfizer Inc.",
            "Transition from a private entity to a public company, increasing scrutiny and regulatory obligations."
          ],
          "environmental_issues": [],
          "social_issues": [
            "Commitment to improving the lives of patients with life-altering immune and inflammatory diseases."
          ],
          "governance_issues": [
            "Increased regulatory obligations and scrutiny following the transition to a public company."
          ],
          "recommendation": "caution",
          "confidence_score": 80
        },
        "evidence": {
          "sources": [
            {
              "url": "",
              "title": "Expanded Access Policy - Tourmaline Bio",
              "snippet": "Expanded access will not delay regulatory approval and availability of the investigational drug to a broad patient population. ... learning about our clinical trials to consult their healthcare provider and/or visit clinicaltrials.gov and search for Tourmaline Bio. \u00a92025 Tourmaline Bio, Inc. Contact 27 West 24th Street, Suite 702 New York, New ...",
              "domain": "",
              "source_type": "web",
              "category": "financial_legal",
              "query_context": "Tourmaline Bio Inc. Tourmaline Bio Inc. regulatory approval delays",
              "retrieved_at": "2025-01-06T21:09:06.167928+00:00",
              "published_date": null,
              "source_hash": "2b472be52739fd393a8fdb76cbb3642d"
            },
            {
              "url": "",
              "title": "SEC Filing - Tourmaline Bio, Inc.",
              "snippet": "\"2023 was a transformational year for Tourmaline. We became a public company and continued our efforts to lead an IL-6 renaissance with TOUR006, which we believe can achieve a best-in-class profile by providing a long-acting, patient-friendly treatment through low-volume subcutaneous injections,\" said Sandeep Kulkarni, MD, Co-Founder and Chief Executive Officer of Tourmaline.",
              "domain": "",
              "source_type": "web",
              "category": "financial_legal",
              "query_context": "Tourmaline Bio Inc. Tourmaline Bio Inc. regulatory approval delays",
              "retrieved_at": "2025-01-06T21:09:06.168044+00:00",
              "published_date": null,
              "source_hash": "0d53a9eb4d52a3be9ab44c028980d1c9"
            },
            {
              "url": "",
              "title": "SEC Filings - Tourmaline Bio, Inc.",
              "snippet": "Contact 27 West 24th Street, Suite 702 New York, New York 10010. info@tourmalinebio.com",
              "domain": "",
              "source_type": "web",
              "category": "financial_legal",
              "query_context": "Tourmaline Bio Inc. Tourmaline Bio Inc. intellectual property disputes",
              "retrieved_at": "2025-01-06T21:09:09.860686+00:00",
              "published_date": null,
              "source_hash": "662824efa86719188ab0526865b6b576"
            },
            {
              "url": "",
              "title": "tourmalinecorporateoverv - SEC.gov",
              "snippet": "The material in this presentation regarding Tourmaline Bio, Inc. (\"we,\" \"us\" or the \"Company\") is for informational purposes only. ... the timing and likelihood of seeking regulatory approval for the Company's product candidates, including pacibekitug; the timing of submitting investigational new drug applications and other ...",
              "domain": "",
              "source_type": "web",
              "category": "financial_legal",
              "query_context": "Tourmaline Bio Inc. Tourmaline Bio Inc. regulatory approval delays",
              "retrieved_at": "2025-01-06T21:09:06.168173+00:00",
              "published_date": null,
              "source_hash": "607eb379c71b32bd169ebba1c1e50ae5"
            },
            {
              "url": "",
              "title": "SEC Filing - Tourmaline Bio, Inc.",
              "snippet": "NEW YORK - Dec. 10, 2024 - Tourmaline Bio, Inc. (Tourmaline) (NASDAQ: TRML), a late-stage clinical biotechnology company developing transformative medicines to dramatically improve the lives of patients with life-altering immune and inflammatory diseases, today is hosting its Investor Day, beginning at 10 a.m. ET, during which it will outline progress across its pipeline and provide ...",
              "domain": "",
              "source_type": "web",
              "category": "financial_legal",
              "query_context": "Tourmaline Bio Inc. Tourmaline Bio Inc. regulatory approval delays",
              "retrieved_at": "2025-01-06T21:09:06.168241+00:00",
              "published_date": null,
              "source_hash": "8eca4c2c0ca691e9910b542155f6fd24"
            },
            {
              "url": "",
              "title": "Tourmaline Bio, Inc. SEC 10-Q Report \u2014 TradingView News",
              "snippet": "Tourmaline Bio, Inc., a biotechnology company focused on developing transformative medicines for immune and inflammatory diseases, has released its Form 10-Q report for the quarter ended September 30, 2023. ... If the company is unable to successfully complete clinical development, obtain regulatory approval, or commercialize pacibekitug or any ...",
              "domain": "",
              "source_type": "web",
              "category": "financial_legal",
              "query_context": "Tourmaline Bio Inc. Tourmaline Bio Inc. regulatory approval delays",
              "retrieved_at": "2025-01-06T21:09:06.168257+00:00",
              "published_date": null,
              "source_hash": "c957e26649a4d9eafe8dc28d97bd5eab"
            },
            {
              "url": "",
              "title": "Tourmaline Bio, Inc. - AnnualReports.com",
              "snippet": "Tourmaline Bio, Inc. Ticker TRML. Exchange NASDAQ More. ... Based in New York City, New York; Tourmaline is a late-stage clinical biotechnology company driven by its mission to develop transformative medicines that dramatically improve the lives of patients with life-altering immune and inflammatory diseases. Tourmaline's lead asset is TOUR006.",
              "domain": "",
              "source_type": "web",
              "category": "financial_legal",
              "query_context": "Tourmaline Bio Inc. Tourmaline Bio Inc. intellectual property disputes",
              "retrieved_at": "2025-01-06T21:09:09.860767+00:00",
              "published_date": null,
              "source_hash": "858e197018bfa3775c4ab0d163410233"
            },
            {
              "url": "",
              "title": "Tourmaline Bio Announces Proposed Public Offering of Common Stock",
              "snippet": "About Tourmaline Bio, Inc. ... as well as risks associated with the clinical development and regulatory approval of product candidates, including potential delays in the commencement, enrollment ...",
              "domain": "",
              "source_type": "web",
              "category": "financial_legal",
              "query_context": "Tourmaline Bio Inc. Tourmaline Bio Inc. regulatory approval delays",
              "retrieved_at": "2025-01-06T21:09:06.168289+00:00",
              "published_date": null,
              "source_hash": "d9c291d2d5a6bb261a3adf7acfef2136"
            },
            {
              "url": "",
              "title": "Tourmaline Bio, Inc. Common Stock (TRML) SEC Filings - Nasdaq",
              "snippet": "Find the latest SEC Filings data for Tourmaline Bio, Inc. Common Stock (TRML) at Nasdaq.com.",
              "domain": "",
              "source_type": "web",
              "category": "financial_legal",
              "query_context": "Tourmaline Bio Inc. Tourmaline Bio Inc. intellectual property disputes",
              "retrieved_at": "2025-01-06T21:09:09.860786+00:00",
              "published_date": null,
              "source_hash": "491c39749dfc641c17dccc3d33eb76b9"
            },
            {
              "url": "",
              "title": "License Agreement by and between Tourmaline Bio, LLC and Pfizer Inc ...",
              "snippet": "License Agreement by and between Tourmaline Bio, LLC and Pfizer Inc., dated May 3, 2022 from Talaris Therapeutics, Inc. filed with the Securities and Exchange Commission. ... in such country to market and sell such product as a biopharmaceutical product through reference to the MAA and Regulatory Approval of the Reference Product pursuant to an ...",
              "domain": "",
              "source_type": "web",
              "category": "financial_legal",
              "query_context": "Tourmaline Bio Inc. Tourmaline Bio Inc. regulatory approval delays",
              "retrieved_at": "2025-01-06T21:09:06.168309+00:00",
              "published_date": null,
              "source_hash": "98138c2c49fa15d7674d19facf6a7841"
            },
            {
              "url": "",
              "title": "Leerink Partnrs Expects Stronger Earnings for Tourmaline Bio",
              "snippet": "Leerink Partnrs increased their FY2025 EPS estimates for shares of Tourmaline Bio in a note issued to investors on Wednesday, December 11th. Leerink Partnrs analyst T. Smith now expects that the company will earn ($3.",
              "domain": "",
              "source_type": "news",
              "category": "financial_legal",
              "query_context": "Tourmaline Bio Inc. Tourmaline Bio Inc. regulatory approval delays",
              "retrieved_at": "2025-01-06T21:09:08.323838+00:00",
              "published_date": "2024-12-14T06:11:00+00:00",
              "source_hash": "7e4768c383771a730a26993199aa4e2b"
            },
            {
              "url": "",
              "title": "Tourmaline Bio Highlights Cardiovascular Inflammation Focus and Announces Key Clinical and Strategic Updates at Investor Day",
              "snippet": "Tourmaline Bio, Inc. (Tourmaline) (NASDAQ: TRML), a late-stage clinical biotechnology company developing transformative medicines to dramatically improve the lives of patients with life-altering ...",
              "domain": "",
              "source_type": "news",
              "category": "financial_legal",
              "query_context": "Tourmaline Bio Inc. Tourmaline Bio Inc. intellectual property disputes",
              "retrieved_at": "2025-01-06T21:09:12.362227+00:00",
              "published_date": "2024-12-10T08:30:00+00:00",
              "source_hash": "ae4ef4b071aa2b29ebcd12482d0e6a61"
            },
            {
              "url": "",
              "title": "Tourmaline Bio, Inc. (NASDAQ:TRML) Shares Bought by Barclays PLC",
              "snippet": "Barclays PLC increased its position in shares of Tourmaline Bio, Inc. (NASDAQ:TRML - Free Report) by 283.7% in the 3rd quarter, according to its most recent disclosure with the SEC. The institutional investor owned 31,",
              "domain": "",
              "source_type": "news",
              "category": "ethical_social",
              "query_context": "Tourmaline Bio Inc. Tourmaline Bio Inc. clinical trial adverse events",
              "retrieved_at": "2025-01-06T21:09:16.404921+00:00",
              "published_date": "2025-01-01T07:23:00+00:00",
              "source_hash": "27ab8ab6a0b211dea388c46fb40a4bfa"
            },
            {
              "url": "",
              "title": "Tourmaline Bio, Inc. (TRML)",
              "snippet": "Tourmaline Bio, Inc. ( (TRML) ) has released its Q3 earnings. Here is a breakdown of the information Tourmaline Bio, Inc. presented to its investors. Tourmaline Bio, Inc. is a clinical-stage ...",
              "domain": "",
              "source_type": "news",
              "category": "financial_legal",
              "query_context": "Tourmaline Bio Inc. Tourmaline Bio Inc. intellectual property disputes",
              "retrieved_at": "2025-01-06T21:09:12.362125+00:00",
              "published_date": "2025-01-02T00:00:00+00:00",
              "source_hash": "f80897bb9dbfd88f136c38f83ed4089e"
            },
            {
              "url": "",
              "title": "Tourmaline Bio Updates on Clinical Progress and Outlook",
              "snippet": "Tourmaline Bio, Inc. operates in the biotechnology industry, focusing on developing transformative medicines for immune and inflammatory diseases. Their lead product candidate, pacibekitug ...",
              "domain": "",
              "source_type": "news",
              "category": "financial_legal",
              "query_context": "Tourmaline Bio Inc. Tourmaline Bio Inc. intellectual property disputes",
              "retrieved_at": "2025-01-06T21:09:12.362238+00:00",
              "published_date": "2024-12-10T21:33:00+00:00",
              "source_hash": "3ba2454a4b298211052e6e6c481c9ecd"
            },
            {
              "url": "",
              "title": "SEC Filing - Tourmaline Bio, Inc.",
              "snippet": "In September 2022, Tourmaline Bio, LLC was converted to Tourmaline Bio, Inc. Tourmaline's principal executive offices are located at 27 West 24 th Street, Suite 702 New York, NY 10010, and its telephone number is (646) 481-9832. Merger Sub",
              "domain": "",
              "source_type": "web",
              "category": "financial_legal",
              "query_context": "Tourmaline Bio Inc. Tourmaline Bio Inc. intellectual property disputes",
              "retrieved_at": "2025-01-06T21:09:09.860730+00:00",
              "published_date": null,
              "source_hash": "a3b95d1b5f3ddfaeef8bbc724784fe8b"
            },
            {
              "url": "",
              "title": "License Agreement by and between Tourmaline Bio, LLC and Pfizer Inc ...",
              "snippet": "License Agreement by and between Tourmaline Bio, LLC and Pfizer Inc., dated May 3, 2022 from Talaris Therapeutics, Inc. filed with the Securities and Exchange Commission. ... with respect to any Intellectual Property Rights or other rights to provide data or other information, ... Any disputes, controversies or other claims arising out of this ...",
              "domain": "",
              "source_type": "web",
              "category": "financial_legal",
              "query_context": "Tourmaline Bio Inc. Tourmaline Bio Inc. intellectual property disputes",
              "retrieved_at": "2025-01-06T21:09:09.860744+00:00",
              "published_date": null,
              "source_hash": "3b33a23d9aa6c6167775329364936a1f"
            },
            {
              "url": "",
              "title": "SEC Filing - Tourmaline Bio, Inc.",
              "snippet": "On October 19, 2023, Talaris completed its previously announced merger transaction in accordance with the terms and conditions of the Agreement and Plan of Merger, dated as of June 22, 2023 (the \"Merger Agreement\"), by and among Talaris, Tourmaline Sub, Inc. (formerly known as Tourmaline Bio, Inc., \"Legacy Tourmaline\") and Terrain ...",
              "domain": "",
              "source_type": "web",
              "category": "financial_legal",
              "query_context": "Tourmaline Bio Inc. Tourmaline Bio Inc. intellectual property disputes",
              "retrieved_at": "2025-01-06T21:09:09.860756+00:00",
              "published_date": null,
              "source_hash": "c7feea2d3e04d4195dba50a37a6efed3"
            },
            {
              "url": "",
              "title": "Tourmaline Bio, Inc. (TRML) Company Profile & Facts - Yahoo Finance",
              "snippet": "Tourmaline Bio, Inc. was founded in 2021 and is headquartered in New York, New York. Corporate Governance Tourmaline Bio, Inc.'s ISS Governance QualityScore as of January 1, 2025 is 9.",
              "domain": "",
              "source_type": "web",
              "category": "financial_legal",
              "query_context": "Tourmaline Bio Inc. Tourmaline Bio Inc. intellectual property disputes",
              "retrieved_at": "2025-01-06T21:09:09.860777+00:00",
              "published_date": null,
              "source_hash": "336daa27e057634642343bec6279a543"
            },
            {
              "url": "",
              "title": "Tourmaline Bio, Inc. Company Profile - Dun & Bradstreet",
              "snippet": "Find company research, competitor information, contact details & financial data for Tourmaline Bio, Inc. of New York, NY. Get the latest business insights from Dun & Bradstreet. Tourmaline Bio, Inc. D&B Business Directory HOME / BUSINESS ... Residential Intellectual and Developmental Disability, Mental Health, ...",
              "domain": "",
              "source_type": "web",
              "category": "financial_legal",
              "query_context": "Tourmaline Bio Inc. Tourmaline Bio Inc. intellectual property disputes",
              "retrieved_at": "2025-01-06T21:09:09.860794+00:00",
              "published_date": null,
              "source_hash": "7d7b9e974ef225befadcd8965341bf75"
            },
            {
              "url": "",
              "title": "Terms of Use - Tourmaline Bio",
              "snippet": "Company expressly retains all ownership rights, title and interest in and to all aspects of the Site and all intellectual property rights therein, including, but not limited to, all current and future patents, copyrights, trademarks, trade secrets, know-how, and other proprietary rights included or embodied in the Site. 1.3 Restrictions.",
              "domain": "",
              "source_type": "web",
              "category": "financial_legal",
              "query_context": "Tourmaline Bio Inc. Tourmaline Bio Inc. intellectual property disputes",
              "retrieved_at": "2025-01-06T21:09:09.860804+00:00",
              "published_date": null,
              "source_hash": "63bb1c2ad6da7737671bd56f29a59b2f"
            },
            {
              "url": "",
              "title": "Home - Tourmaline Bio",
              "snippet": "Pipeline We seek to develop medicines that have the potential to establish new standards-of-care in areas of high unmet medical need. Our Team We are a nimble, driven and accomplished team of entrepreneurs, physicians, and industry experts with a mission to thoughtfully develop transformative medicines that dramatically improve the lives of patients with life-altering immune [\u2026]",
              "domain": "",
              "source_type": "web",
              "category": "financial_legal",
              "query_context": "Tourmaline Bio Inc. Tourmaline Bio Inc. intellectual property disputes",
              "retrieved_at": "2025-01-06T21:09:09.860813+00:00",
              "published_date": null,
              "source_hash": "ddeeb5de9c425f943e0f45e724e4f6d8"
            },
            {
              "url": "",
              "title": "Analysts Set Tourmaline Bio, Inc. (NASDAQ:TRML) Price Target at $54.00",
              "snippet": "Tourmaline Bio has a 52 week low of $12.12 and a 52 week high of $48.31. The stock has a market cap of $529.27 million, a price-to-earnings ratio of -7.32 and a beta of 2.32.",
              "domain": "",
              "source_type": "news",
              "category": "financial_legal",
              "query_context": "Tourmaline Bio Inc. Tourmaline Bio Inc. intellectual property disputes",
              "retrieved_at": "2025-01-06T21:09:12.362218+00:00",
              "published_date": "2025-01-03T00:00:00+00:00",
              "source_hash": "eeda47ab4daa9898eb6e07e5b06bce42"
            },
            {
              "url": "",
              "title": "Tourmaline Bio Initiates Clinical Development of TOUR006 for ...",
              "snippet": "NEW YORK, May 16, 2024 (GLOBE NEWSWIRE) -- Tourmaline Bio, Inc. (Tourmaline) (NASDAQ: TRML), a late-stage clinical biotechnology company developing transformative medicines to dramatically improve the lives of patients with life-altering immune and inflammatory diseases, today announced that the first patient has been dosed in its Phase 2 ...",
              "domain": "",
              "source_type": "web",
              "category": "ethical_social",
              "query_context": "Tourmaline Bio Inc. Tourmaline Bio Inc. clinical trial adverse events",
              "retrieved_at": "2025-01-06T21:09:13.847685+00:00",
              "published_date": null,
              "source_hash": "d2de231c88fda3f9825309a4159fcdec"
            },
            {
              "url": "",
              "title": "Disease Focus - Tourmaline Bio",
              "snippet": "Multiple clinical and human genetic studies have implicated elevated IL-6 levels with risk of future major adverse cardiovascular events. Adapted from: Libby et al., Cells (2021) ... \u00a92025 Tourmaline Bio, Inc. Contact 27 West 24th Street, Suite 702 New York, New York 10010 info@tourmalinebio.com.",
              "domain": "",
              "source_type": "web",
              "category": "ethical_social",
              "query_context": "Tourmaline Bio Inc. Tourmaline Bio Inc. clinical trial adverse events",
              "retrieved_at": "2025-01-06T21:09:13.847787+00:00",
              "published_date": null,
              "source_hash": "e0936240f683aa1c97bddeb9eb447083"
            },
            {
              "url": "",
              "title": "Tourmaline Bio, Inc. - Drug pipelines, Patents, Clinical trials - Synapse",
              "snippet": "Explore Tourmaline Bio, Inc. with its drug pipeline, therapeutic area, technology platform, 14 clinical trials, 81 news, and 9 literature, Disease Domain:Immune System Diseases, Endocrinology and Metabolic Disease, Technology Platform:Monoclonal antibody, Hematopoietic stem cell therapy, Drug:TOUR-006, FCR-002, Enriched hematopoietic stem cell (Talaris Therapeutics), Enriched hematopoetic stem ...",
              "domain": "",
              "source_type": "web",
              "category": "ethical_social",
              "query_context": "Tourmaline Bio Inc. Tourmaline Bio Inc. clinical trial adverse events",
              "retrieved_at": "2025-01-06T21:09:13.847804+00:00",
              "published_date": null,
              "source_hash": "54773ad4d9b1f5d4e05941ce91d32279"
            },
            {
              "url": "",
              "title": "Pipeline - Tourmaline Bio",
              "snippet": "Note: Hatched bars represent trials that have not yet commenced We continue to seek additional opportunities for pacibekitug (also known as TOUR006). We continue to identify indications where IL-6 inhibition has shown evidence of clinical benefit despite no formal industry-led development programs as well as indications where we could bring pacibekitug's differentiated profile forward ...",
              "domain": "",
              "source_type": "web",
              "category": "ethical_social",
              "query_context": "Tourmaline Bio Inc. Tourmaline Bio Inc. clinical trial adverse events",
              "retrieved_at": "2025-01-06T21:09:13.847816+00:00",
              "published_date": null,
              "source_hash": "b80286e2654bb225b9fb283e0e248529"
            },
            {
              "url": "",
              "title": "Tourmaline Bio Initiates Clinical Development of TOUR006 for ...",
              "snippet": "Tourmaline Bio Initiates Clinical Development of TOUR006 for Cardiovascular Diseases with First Patient Dosed in Phase 2 TRANQUILITY Trial Tourmaline Bio, Inc. Thu, May 16, 2024, 7:00 AM 6 min read",
              "domain": "",
              "source_type": "web",
              "category": "ethical_social",
              "query_context": "Tourmaline Bio Inc. Tourmaline Bio Inc. clinical trial adverse events",
              "retrieved_at": "2025-01-06T21:09:13.847828+00:00",
              "published_date": null,
              "source_hash": "b294695ea80a0ae8c771bfe97d09f9da"
            },
            {
              "url": "",
              "title": "Tourmaline Bio Announces Expected Upcoming Key Milestones for the ...",
              "snippet": "Tourmaline Bio, Inc. Tourmaline plans to accelerate the initiation of a pivotal Phase 3 trial in 2024 evaluating subcutaneous TOUR006 every 8 weeks as first-line treatment for TED, with topline ...",
              "domain": "",
              "source_type": "web",
              "category": "ethical_social",
              "query_context": "Tourmaline Bio Inc. Tourmaline Bio Inc. clinical trial adverse events",
              "retrieved_at": "2025-01-06T21:09:13.847839+00:00",
              "published_date": null,
              "source_hash": "0a744a3e64559c6414f101ff262cfa69"
            },
            {
              "url": "",
              "title": "Tourmaline Bio Initiates Clinical Development of TOUR006 for ...",
              "snippet": "NEW YORK, May 16, 2024 (GLOBE NEWSWIRE) -- Tourmaline Bio, Inc. (Tourmaline) (NASDAQ: TRML), a late-stage clinical biotechnology company developing transformative medicines to dramatically improve ...",
              "domain": "",
              "source_type": "web",
              "category": "ethical_social",
              "query_context": "Tourmaline Bio Inc. Tourmaline Bio Inc. clinical trial adverse events",
              "retrieved_at": "2025-01-06T21:09:13.847848+00:00",
              "published_date": null,
              "source_hash": "26717c30e2ee3d64679b394440436a73"
            },
            {
              "url": "",
              "title": "Tourmaline Bio Announces FDA Clearance of Investigational - GlobeNewswire",
              "snippet": "To date, TOUR006 has been studied in over 400 autoimmune patients across six clinical trials. Tourmaline plans to develop TOUR006 in thyroid eye disease (TED) and atherosclerotic cardiovascular ...",
              "domain": "",
              "source_type": "web",
              "category": "ethical_social",
              "query_context": "Tourmaline Bio Inc. Tourmaline Bio Inc. clinical trial adverse events",
              "retrieved_at": "2025-01-06T21:09:13.847857+00:00",
              "published_date": null,
              "source_hash": "619b652ee45dc792b43249a676cfbfeb"
            },
            {
              "url": "",
              "title": "Tourmaline Bio Highlights Cardiovascular Inflammation Focus and ...",
              "snippet": "NEW YORK, Dec. 10, 2024 (GLOBE NEWSWIRE) -- Tourmaline Bio, Inc. (Tourmaline) (NASDAQ: TRML), a late-stage clinical biotechnology company developing transformative medicines to dramatically ...",
              "domain": "",
              "source_type": "web",
              "category": "ethical_social",
              "query_context": "Tourmaline Bio Inc. Tourmaline Bio Inc. clinical trial adverse events",
              "retrieved_at": "2025-01-06T21:09:13.847866+00:00",
              "published_date": null,
              "source_hash": "616c34cde388d41f11416be69f16684a"
            },
            {
              "url": "",
              "title": "FDA grants clearance to Tourmaline Bio's IND ... - Clinical Trials Arena",
              "snippet": "The US Food and Drug Administration (FDA) has granted clearance to Tourmaline Bio's investigational new drug (IND) application enabling initiation of a Phase IIb trial of TOUR006 to treat thyroid eye disease (TED) also known as Graves' ophthalmopathy.. The planned study intends to assess TOUR006 20mg and 50mg doses against placebo in moderate to severe TED patients who are in the active ...",
              "domain": "",
              "source_type": "web",
              "category": "ethical_social",
              "query_context": "Tourmaline Bio Inc. Tourmaline Bio Inc. clinical trial adverse events",
              "retrieved_at": "2025-01-06T21:09:13.847875+00:00",
              "published_date": null,
              "source_hash": "289a64c014a28715863c33f7c69438c4"
            },
            {
              "url": "",
              "title": "Tourmaline Bio Unveils Clinical Progress and New Indication",
              "snippet": "Pick the best stocks and maximize your portfolio: Discover top-rated stocks from highly ranked analysts with Analyst Top Stocks! Easily identify outperforming stocks and invest smarter with Top ...",
              "domain": "",
              "source_type": "news",
              "category": "ethical_social",
              "query_context": "Tourmaline Bio Inc. Tourmaline Bio Inc. clinical trial adverse events",
              "retrieved_at": "2025-01-06T21:09:16.404847+00:00",
              "published_date": "2024-12-10T08:01:00+00:00",
              "source_hash": "ec3a703879110313cb08961ab2abbaf9"
            },
            {
              "url": "",
              "title": "Tourmaline Bio Updates on Clinical Progress and Outlook",
              "snippet": "Tourmaline Bio has released an updated corporate presentation detailing its progress and future plans, including significant clinical trial milestones ... Tourmaline Bio, Inc. operates in the ...",
              "domain": "",
              "source_type": "news",
              "category": "ethical_social",
              "query_context": "Tourmaline Bio Inc. Tourmaline Bio Inc. clinical trial adverse events",
              "retrieved_at": "2025-01-06T21:09:16.404891+00:00",
              "published_date": "2024-12-10T21:33:00+00:00",
              "source_hash": "ebade8eae785f47ae55bdcf2b3d2bddf"
            },
            {
              "url": "",
              "title": "Tourmaline Bio Highlights Cardiovascular Inflammation Focus and Announces Key Clinical and Strategic Updates at Investor Day",
              "snippet": "Phase 2 TRANQUILITY trial surpasses enrollment ... 2024 (GLOBE NEWSWIRE) -- Tourmaline Bio, Inc. (Tourmaline) (NASDAQ: TRML), a late-stage clinical biotechnology company developing transformative ...",
              "domain": "",
              "source_type": "news",
              "category": "ethical_social",
              "query_context": "Tourmaline Bio Inc. Tourmaline Bio Inc. clinical trial adverse events",
              "retrieved_at": "2025-01-06T21:09:16.404902+00:00",
              "published_date": "2024-12-10T00:00:00+00:00",
              "source_hash": "b5c1e96956c7d343d4525a0d3e151c27"
            },
            {
              "url": "",
              "title": "Analysts Set Tourmaline Bio, Inc. (NASDAQ:TRML) Price Target at $54.00",
              "snippet": "Tourmaline Bio, Inc operates as a clinical biotechnology company that develops medicines for patients with life-altering immune and inflammatory diseases. It develops TOUR006, a human anti-IL-6 ...",
              "domain": "",
              "source_type": "news",
              "category": "ethical_social",
              "query_context": "Tourmaline Bio Inc. Tourmaline Bio Inc. clinical trial adverse events",
              "retrieved_at": "2025-01-06T21:09:16.404913+00:00",
              "published_date": "2025-01-03T00:00:00+00:00",
              "source_hash": "1a554c49108789558f68bf0a238e02a5"
            }
          ],
          "queries": [
            {
              "category": "financial_legal",
              "query": "Tourmaline Bio Inc. regulatory approval delays",
              "rationale": "Investigate potential delays or rejections in clinical trials or regulatory approvals that could impact the company\u2019s timeline and financial stability",
              "priority": 1
            },
            {
              "category": "financial_legal",
              "query": "Tourmaline Bio Inc. intellectual property disputes",
              "rationale": "Check for any legal challenges related to patents or proprietary technologies that could affect the company\u2019s operations",
              "priority": 2
            },
            {
              "category": "ethical_social",
              "query": "Tourmaline Bio Inc. clinical trial adverse events",
              "rationale": "Look for reports of adverse events or ethical concerns in ongoing clinical trials that could harm the company\u2019s reputation",
              "priority": 3
            }
          ]
        },
        "categorization": {
          "product_issues": [],
          "conduct_issues": [],
          "tags": [],
          "patterns": {}
        }
      },
      "metadata": {
        "analysis_timestamp": "2025-01-06T14:09:32.174287",
        "data_confidence": 80,
        "pattern_confidence": null
      }
    }
  ]
}